Drugs / Ranirestat
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial · 1 missed | ||||||
| Phase 2/3 | NCT00927914 | Jul 2009 → Jan 2013 | diabetic polyneuropathy | Eisai Inc. | Completed | Missed primary |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT00101426 | Oct 2004 → Sep 2006 | diabetic neuropathy | Sumitomo Pharma Co., Ltd. | Completed | Met primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2011-05-11 | Sumitomo Pharma America, Inc. | Results Results of a Phase II Clinical Trial for Ranirestat - Therapeutic Agent for Diabetic Complications sumitomo-pharma.com ↗
The results of the trial showed that although a clear dose response relationship was not established, a significant increase in summed nerve conduction velocity as the primary endpoint was seen in all ranirestat arms compared to before administration. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2011-05-11 | Sumitomo Pharma America, Inc. | Results of a Phase II Clinical Trial for Ranirestat - Therapeutic Agent for Diabetic Complications sumitomo-pharma.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ranirestat | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00101426 ↗ |
| Known as | AS-3201 | “This is a safety and efficacy trial of ranirestat(AS-3201) which is an aldose reductase inhibitor in patients with diabetic sensorimotor polyneuropathy.” NCT00101426 ↗ |
| Action | Inhibit | “This is a safety and efficacy trial of ranirestat(AS-3201) which is an aldose reductase inhibitor in patients with diabetic sensorimotor polyneuropathy.” NCT00101426 ↗ |
| Modality | Small molecule | — CHEMBL334830 ↗ |
| Route | Oral | “given orally” NCT00927914 ↗ |